首页> 美国卫生研究院文献>other >Impact of nivolumab vs standard single-agent therapy of investigator’s choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from CheckMate 141 a randomized phase 3 trial

【2h】

Impact of nivolumab vs standard single-agent therapy of investigator’s choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from CheckMate 141 a randomized phase 3 trial

机译：尼古鲁单抗与标准的单药治疗对研究者选择的治疗对头颈部复发或转移性鳞状细胞癌患者报告的结局的影响：一项与健康相关的生活质量研究来自CheckMate 141（一项随机3期临床试验）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

著录项
引文网络
相似文献
相关主题

著录项

期刊名称 other
作者
Kevin J Harrington; Robert L Ferris; George Blumenschein Jr; A Dimitrios Colevas; Jerome Fayette; Lisa Licitra; Stefan Kasper; Caroline Even; Everett E Vokes; Francis Worden; Nabil F Saba; Naomi Kiyota; Robert Haddad; Makoto Tahara; Viktor Grünwald; James W Shaw; Manish Monga; Mark Lynch; Fiona Taylor; Michael DeRosa; Laura Morrissey; Kim Cocks; Maura L Gillison; Joel Guigay;
展开▼
作者单位

展开▼
年(卷),期 -1(18),8
年度 -1
页码 1104–1115
总页数 21
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
专利

1. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial [J] . Harrington Kevin J., Ferris Robert L., Blumenschein George Jr., The lancet oncology . 2017,第8期

机译：Nivolumab与标准，调查员在颈部复发或转移性鳞状细胞癌中的选择（Checkmate 141）：与随机阶段3审判的健康相关的生活质量结果
2. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial [J] . Harrington Kevin J., Ferris Robert L., Blumenschein George Jr., Journal of Turbulence . 2017,第8期

机译：Nivolumab与标准，调查员在颈部复发或转移性鳞状细胞癌中的选择（Checkmate 141）：与随机阶段3审判的健康相关的生活质量结果
3. Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial [J] . Haddad Robert, Concha‐Benavente Fernando, Blumenschein George, Cancer: A Journal of the American Cancer Society . 2019,第18期

机译：Nivolumab治疗超越复发性或转移性鳞状细胞癌的再生或转移鳞状细胞癌中的再现或颈部中的治疗方法141：随机相3临床试验的亚组分析
4. Interstitial photodynamic therapy in combination with Cetuximab for recurrent head and neck squamous cell carcinoma [C] . Nestor Rigual, Ambujakshan Dildeep, Gal Shafirstein Conference on photonic therapeutics and diagnostics IX . 2013

机译：间质性光动力疗法联合西妥昔单抗治疗复发性头颈部鳞状细胞癌
5. Inflammatory mechanisms of chemokine receptor 7 expression in metastatic squamous cell carcinoma of the head and neck (SCCHN). [D] . Mburu, Yvonne K. 2011

机译：趋化因子受体7在头颈部转移性鳞状细胞癌（SCCHN）中表达的炎症机制。
6. Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial [O] . Robert Haddad, Fernando Concha‐Benavente, George Blumenschein Jr, -1

机译：CheckMate 141中在头颈部复发或转移性鳞状细胞癌中超过RECIST定义进展的Nivolumab治疗：一项随机3期临床试验的亚组分析
7. Two-year Update From CheckMate 141: Outcomes With Nivolumab (Nivo) vs Investigator's Choice (IC) in Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) in the Overall Population and PD-L1 Subgroups [O] . R.L. Ferris, G.R. Blumenschein, J. Fayette, 2018

机译：来自Checkmate 141的两年更新：患有Nivolumab（Nivo）的结果对核和颈部（SCCHN）的复发性或转移性（R / M）鳞状细胞癌（SCCHN）中的反复化或调查仪的选择（IC）

Impact of nivolumab vs standard single-agent therapy of investigator’s choice on patient-reported outcomes in recurrent or metastatic squamous cell carcinoma of the head and neck: health-related quality-of-life results from CheckMate 141 a randomized phase 3 trial

著录项

引文网络

相似文献

相关主题

期刊订阅